<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5731318</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Effect of Treatment Strategy of Chronic Ischemic Mitral
Regurgitation on Long-Term Outcomes in Coronary Artery Bypass
Grafting</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>&#x0015e;a&#x0015f;kin</surname><given-names>H&#x000fc;seyin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Ozcan</surname><given-names>Kaz&#x00131;m Serhan</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>&#x00130;diz</surname><given-names>Mustafa</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Cardiovascular Surgery of Derince Training and
Research Hospital, Kocaeli, Turkey.</aff><aff id="aff2">
<label>2</label> Department of Cardiology of Derince Training and Research Hospital,
Kocaeli, Turkey.</aff><aff id="aff3">
<label>3</label> Department of Cardiovascular Surgery of Acibadem &#x00130;zmit Hospital,
Kocaeli, Turkey.</aff><author-notes><corresp id="c1">Correspondence Address: Huseyin Saskin, Derince Training and
Research Hospital - Department of Cardiovascular Surgery &#x00130;bnisina Mahallesi, SSK
Hst., 41900 - Derince/Kocaeli, Turkey. E-mail: <email>sueda_hs@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Oct-Dec</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2017</year></pub-date><volume>32</volume><issue>6</issue><fpage>508</fpage><lpage>516</lpage><history><date date-type="received"><day>02</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>06</day><month>9</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To investigate the mid- and long-term outcomes of case-based selective
strategy of mitral ring annuloplasty during coronary artery bypass grafting
in patients with coronary artery disease accompanied by chronic ischemic
mitral regurgitation.</p></sec><sec><title>Methods</title><p>132 patients who were diagnosed ischemic moderate to severe mitral
regurgitation undergoing coronary artery bypass grafting in the same center
with the same surgical team were divided into 2 groups and investigated
retrospectively. Patients undergoing simultaneous mitral ring annuloplasty
and coronary artery bypass grafting were enrolled to group 1 (n=58),
patients undergoing isolated coronary artery bypass grafting were enrolled
in group 2 (n=74).</p></sec><sec><title>Results</title><p>The mean age of the patients were 65.0 &#x000b1; 9.4 years and 39 (29.5%) of
them were female. Preoperative New York Heart Association (NHYA) class
(<italic>P</italic>=0.0001), atrial fibrillation
(<italic>P</italic>=0.006) and the grade of mitral regurgitation
(<italic>P</italic>=0.0001) were significantly different between the
groups. Hospitalization for heart failure was required in 6 (10.6%) patients
in group 1 and 19 (27.1%) patients in Group 2 (<italic>P</italic>=0.02).
Hospital mortality and one-month postoperative mortality occurred in 2
(3.4%) patients in Group 1 and in 4 (5.4%) patients in Group 2
(<italic>P</italic>=0.69). Clinical follow-up was completed with 117
(88.6%) patients.</p></sec><sec><title>Conclusion</title><p>Mitral ring annuloplasty in addition to the coronary artery bypass grafting
is associated with improved NYHA functional class, increased ejection
fraction, decreased residual mitral regurgitation. Further studies are
needed to clarify the role of combined surgery on long-term outcomes. With
proper tools and according to the decisions made by heart teams, both
management strategies can be safely performed.</p></sec></abstract><kwd-group><kwd>Coronary Artery Bypass</kwd><kwd>Mitral Valve Annuloplasty</kwd><kwd>Survival</kwd></kwd-group></article-meta></front><body><table-wrap id="t7" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th colspan="2" align="left" style="background-color:#e6e7e8" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ACE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">=
Angiotensin-converting-enzyme</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEDD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricle
end-diastolic diameter</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ACT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Activated clotting
time</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEDV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricle
end-diastolic volume</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
ejection fraction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVESD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricle
end-systolic diameter</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVESV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricle
end-systolic volume</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ECG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Electrocardiography</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MRA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Mitral ring
annuloplasty</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ejection fraction</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NYHA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= New York Heart
Association</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EROA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Effective regurgitant
orifice area</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PAP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Pulmonary arterial
pressure</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IMI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ischemic mitral valve
insufficiency</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PISA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Proximal isovelocity
surface area</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IMR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ischemic mitral
regurgitation</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Regurgitant volume</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LIMA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left internal mammary
artery</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TTE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transthoracic
echocardiography</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricle</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Chronic ischemic mitral regurgitation (IMR) is an important complication of coronary
artery disease and commonly accompanied by partial or total occlusion of one or two
coronary arteries<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. It is
commonly associated with functional-valve incompetence due to myocardial injury and
adverse left ventricular remodeling, which develops in approximately 50% of patients
after an myocardial infarction, and moderate regurgitation occurs in more than 10%
of patients<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. IMR is associated
with high morbidity and mortality rates, independent of treatment
strategy<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>.</p><p>IMR is commonly accompanied with multivessel coronary artery disease needing surgical
treatment. During coronary artery bypass grafting (CABG), mitral valve intervention
is debated between cardiologists and cardiovascular surgeons and the treatment
strategy were not clearly elucidated in the literature<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. IMR is associated with poor outcomes in patients
undergoing CABG but the outcome of mitral valve intervention during CABG is
controversial<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p><p>Deja et al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> has observed that, in
patients with moderate to severe mitral regurgitation in addition to left ventricle
(LV) dysfunction, mitral repair in addition to CABG is associated with better
survival compared to isolated CABG. In another study, it is observed that isolated
CABG is associated with lower mortality in patients with ischemic mitral
regurgitation<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. In a
study conducted in 355 patients with ischemic mitral regurgitation, Kim et
al.<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup> observed that
survival at 5 years was not different between isolated CABG and CABG in addition to
mitral repair.</p><p>In this study we aimed to investigate the outcome of mitral repair in addition to
CABG on mid- and long-term survival.</p></sec><sec sec-type="methods"><title>METHODS</title><p>In this study, the data of a total of 1640 patients underwent to open cardiac surgery
in a single center by the same surgical team between 2007 and 2014 were investigated
retrospectively. Among these patients, 132 who had coronary artery disease diagnosed
with cardiac catheterization (&#x02265; 75% stenosis in at least one coronary artery)
and moderate to severe (&#x02265; 2 +) ischemic mitral valve insufficiency (IMI)
diagnosed with echocardiography and left ventriculography, and undergoing CABG
and/or mitral ring annuloplasty (MRA) were included in the study. Two groups were
created: Group 1, which included patients who were operated for MRA together with
CABG under cardiopulmonary bypass (CPB) (n=58); and Group 2, which included patients
who were operated for isolated CABG under CPB (n=74).</p><p>Exclusion criteria included any echocardiographic evidence of structural (chordal or
leaflet) mitral valve disease or ruptured papillary muscle. Likewise, patients who
had acute IMI, reoperations for CABG, additional operations for diseases such as
valvular, carotid and peripheral arterial diseases were excluded.</p><p>The controls of the patients included in the study were performed on the
6<sup>th</sup> and 12<sup>th</sup> postoperative months by the same clinician
using transthoracic echocardiography (TTE). All of the patients' follow-up included
measurements of the left ventricular ejection fraction (LVEF), left ventricle
end-diastolic diameter (LVEDD), left ventricle end-systolic diameter (LVESD), left
ventricle end-diastolic volume (LVEDV) and left ventricle end-systolic volume
(LVESV) by Simpson method with TTE. The severity of IMI and evaluation of the mitral
valve functions were done by visual method in all patients. Evaluation of the degree
of IMI was performed by quantitative Doppler echocardiography as it is done the same
as recently<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>. By quantitative
Doppler echocardiography, measurements of stroke volume, regurgitant volume (RV) and
effective regurgitant orifice area (EROA) using proximal isovelocity surface area
(PISA) method were done. Grading the severity of IMI was classified on <xref ref-type="table" rid="t1">Table 1</xref> in parallel with the literature.
Intraoperative transesophageal echocardiography was performed during surgery in all
patients and residual mitral regurgitation was evaluated after repair<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Patients who had moderate (Grade
II), moderate to severe (Grade III) and severe IMI by echocardiography and clinical
evaluation, but who had a short lifetime expectancy, high operative risk and
severely low LVEF, were operated for isolated CABG operation with the decision of
cardiology and cardiovascular surgery council. Patients whose mitral valves were not
operated were added angiotensin-converting-enzyme (ACE) inhibitors and diuretics for
medical treatment in the postoperative period.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Grading of ischemic mitral regurgitation.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">IMR degree</th><th align="center" rowspan="1" colspan="1">Regurgitant volume (mL)</th><th align="center" rowspan="1" colspan="1">Effective regurgitant orifice area
(mm<sup>2</sup>)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">&#x0003c; 30</td><td align="center" rowspan="1" colspan="1">&#x0003c; 20</td></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">30-44</td><td align="center" rowspan="1" colspan="1">20-29</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">45-59</td><td align="center" rowspan="1" colspan="1">30-39</td></tr><tr><td align="left" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">&#x0003e; 60</td><td align="center" rowspan="1" colspan="1">&#x0003e; 40</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>IMR=ischemic mitral regurgitation</p></fn></table-wrap-foot></table-wrap><p>The demographic and clinical data of the patients were obtained by using the software
system of the hospital for records and archives to investigate the patient files,
epicrisis, operation notes and laboratory results. Age, gender, smoking history,
diabetes, hypertension, hyperlipidemia, LVEF, LVEDD, LVESD, LVESV, LVEDV,
preoperative and postoperative laboratory parameters (hemoglobin, leukocyte count,
thrombocyte count, fasting blood glucose, creatinine) operation information, the
number of grafts used, duration of CPB and aortic cross-clamp, amount of blood
products used and length of stay in the intensive care unit and hospital were
recorded. In addition, New York Heart Association (NYHA) functional class was
analyzed.</p><p>Hypertension was accepted as a blood pressure &#x02265; 140/90 mmHg or usage of
antihypertensive drugs; smoking was accepted positive if the patient had not quitted
smoking for the last one year. Diabetes was accepted as fasting blood glucose
&#x02265; 126 mg/dL or use of antidiabetic drugs, hyperlipidemia was accepted as
total cholesterol &#x0003e; 220 mg/dL and LDL-cholesterol &#x0003e; 130 mg/dL or use of
antihyperlipidemic drugs.</p><p>All of the patients were transferred to intensive care unit intubated. They were
extubated following onset of spontaneous breathing and normalization of orientation
and cooperation if the haemodynamic and respiratory functions were appropriate. If
there was no contraindication, 50 mg/day of metoprolol was started orally to all
patients following the 1<sup>st</sup> postoperative day. The diagnosis of
postoperative atrial fibrillation (AF) was made by standard 12 derivation
electrocardiography (ECG). Mortality during the stay in the hospital following
operation or in the first 30 postoperative days was accepted as postoperative
early-term mortality.</p><p>Functional status was assessed according to NYHA criteria during follow-up. Clinical
follow-up data were collected during patient visits to the department or by
telephone interviews. Operative mortality was defined as death within 30 days of the
index procedure or before discharge. The authors had full access to the data and
take full responsibility for its integrity. All authors have read and agree to the
manuscript as written.</p><p>Written informed consent form was obtained from all the patients included in the
study. This study complied with the Declaration of Helsinki and was carried out
following approval of Ethics Committee for Clinical Trials of Medical Faculty of
Kocaeli University.</p><sec><title>Operative Technique</title><p>Median sternotomy was applied following the routine anesthesia application in the
surgery. Bypass grafts (saphenous vein and left internal mammary artery) were
prepared. Systemic heparinization was ensured by administration of 300 IU/kg
heparin in a fashion that activated clotting time (ACT) was greater than 450
seconds. CPB was performed by clinic aortic arterial-bicaval venous cannulation.
Two-stage cannula was used for venous cannulation for patients who were not
applied mitral ring annuloplasty. In all patients, non-pulsatile roller pump and
membrane oxygenator were used for CPB. Surgical procedures were established in
moderate systemic hypothermia (28-30&#x000ba;C). CPB was applied in a fashion that flow
rate would be 2.2 to 2.5 L/min/m<sup>2</sup>; the mean perfusion pressure would
be between 50 and 80 mmHg, hematocrit values would be between 20% and 25%.
Myocardial protection was achieved via antegrade hypothermic and hyperpotasemic
blood cardioplegic arrest, followed by continuous administration of retrograde
blood cardioplegic solution for the duration of cross-clamping. After
cross-clamp application, the initial distal saphenous vein anastomoses were
performed. This step was followed consecutively by ring implantation, distal
anastomosis of the left internal mammary artery (LIMA). Cross-clamps were
removed after de-airing of the heart. All proximal anastomoses were done in the
heart working under partial clamp in all patients operated on.</p><p>Mitral ring annuloplasty was performed in patients in whom the mitral leaflets
could be coapted. A circular SJM Tailor<sup>TM</sup> Flexible Ring (St. Jude
Medical, Inc. St. Paul, USA) was used in all instances. The appropriate ring
size was determined from measurement of the anterior leaflet. Ring sizes 28 to
32 were used. In each patient, 12 TiCron<sup>TM</sup> 2-0 sutures (Covidien
Syneture; Mansfield, MA, USA) were placed. After CPB was stopped, intraoperative
transesophageal echocardiography was performed in order to rule out substantial
valvular insufficiency. In our study, no patient required mitral
reintervention.</p></sec><sec><title>Statistical Analysis</title><p>Statistical analysis was performed using the SPSS software version 12.0 (SPSS
Inc, Chicago, IL, USA). Among the data measured, those showing normal
distribution were expressed as mean &#x000b1; standard deviation; those that do
not show normal distribution were expressed as median (minimum-maximum). The
data obtained by counting were given as percentages (%). Among the data
measured, the normality of distribution was evaluated by histogram or
Kolmogorov-Smirnov test, the homogeneity of distribution was evaluated by the
Levene's test for equality of variance. Among the data measured, the difference
between the groups was evaluated by Student's t-test in normal and homogenous
distribution and by Mann-Whitney U test in a distribution that is not normal and
homogenous. Among the data obtained by counting, the differences between the
groups were evaluated by parametric or non-parametric Pearson's chi-square test
or Fisher's exact test according to the distribution being parametric or not.
Survival curves were constructed for each group using the Kaplan-Meier method,
and comparisons were made using the log-rank test. A <italic>P</italic> value
&#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>The demographic characteristics and clinical data of the patients were summarized in
<xref ref-type="table" rid="t2">Table 2</xref>. Preoperative NHYA class
(<italic>P</italic>=0.0001), AF (<italic>P</italic>=0.006) and the grade of
mitral regurgitation (<italic>P</italic>=0.0001) were significantly different
between groups. The preoperative blood analysis and hematological parameters of the
patients summarized in <xref ref-type="table" rid="t3">Table 3</xref>. No
significant differences in preoperative blood analysis and hematological parameters
were found between the groups.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Evaluation of groups for preoperative characteristics.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">CABG + mitral annuloplasty Group 1 (n=58)</th><th align="center" rowspan="1" colspan="1">Isolated CABG Group 2 (n=74)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, mean&#x000b1;SD, year</td><td align="center" rowspan="1" colspan="1">64.10&#x000b1;8.74</td><td align="center" rowspan="1" colspan="1">65.66&#x000b1;9.95</td><td align="center" rowspan="1" colspan="1">0.22<xref ref-type="table-fn" rid="TFN5">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Gender, n (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male</td><td align="center" rowspan="1" colspan="1">40 (69.0%)</td><td align="center" rowspan="1" colspan="1">53 (71.6%)</td><td align="center" rowspan="2" colspan="1">0.74<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Female</td><td align="center" rowspan="1" colspan="1">18 (31.0%)</td><td align="center" rowspan="1" colspan="1">21 (28.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">EuroSCORE (st), mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">7.21&#x000b1;1.77</td><td align="center" rowspan="1" colspan="1">6.93&#x000b1;1.14</td><td align="center" rowspan="1" colspan="1">0.73<xref ref-type="table-fn" rid="TFN5">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">PAP (mmHg), mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">42.59&#x000b1;5.15</td><td align="center" rowspan="1" colspan="1">41.01&#x000b1;4.96</td><td align="center" rowspan="1" colspan="1">0.11<xref ref-type="table-fn" rid="TFN5">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA class, mean&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">3.55&#x000b1;0.50</td><td align="center" rowspan="1" colspan="1">2.46&#x000b1;0.62</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN5">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">COPD, n (%)</td><td align="center" rowspan="1" colspan="1">10 (17.2%)</td><td align="center" rowspan="1" colspan="1">9 (9.5%)</td><td align="center" rowspan="1" colspan="1">0.19<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Left main lesion &#x0003e; 50%, n (%)</td><td align="center" rowspan="1" colspan="1">8 (13.8%)</td><td align="center" rowspan="1" colspan="1">13 (17.6)</td><td align="center" rowspan="1" colspan="1">0.56<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Rhythm, n (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Sinus rhythm</td><td align="center" rowspan="1" colspan="1">47 (81.0%)</td><td align="center" rowspan="1" colspan="1">71 (95.9%)</td><td align="center" rowspan="2" colspan="1">0.006<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Atrial fibrillation rhythm</td><td align="center" rowspan="1" colspan="1">11 (19.0%)</td><td align="center" rowspan="1" colspan="1">3 (4.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td align="center" rowspan="1" colspan="1">27 (46.6%)</td><td align="center" rowspan="1" colspan="1">31 (41.9%)</td><td align="center" rowspan="1" colspan="1">0.59<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperlipidemia, n (%)</td><td align="center" rowspan="1" colspan="1">23 (39.7%)</td><td align="center" rowspan="1" colspan="1">31 (41.9%)</td><td align="center" rowspan="1" colspan="1">0.80<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension, n (%)</td><td align="center" rowspan="1" colspan="1">27 (46.6%)</td><td align="center" rowspan="1" colspan="1">40 (54.1%)</td><td align="center" rowspan="1" colspan="1">0.39<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking, n (%)</td><td align="center" rowspan="1" colspan="1">20 (34.5%)</td><td align="center" rowspan="1" colspan="1">27 (36.5%)</td><td align="center" rowspan="1" colspan="1">0.81<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Previous neurological event, n (%)</td><td align="center" rowspan="1" colspan="1">3 (5.2%)</td><td align="center" rowspan="1" colspan="1">5 (6.8%)</td><td align="center" rowspan="1" colspan="1">0.98<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Unstable angina, n (%)</td><td align="center" rowspan="1" colspan="1">21 (36.2%)</td><td align="center" rowspan="1" colspan="1">31 (41.9%)</td><td align="center" rowspan="1" colspan="1">0.51<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Severity of mitral regurgitation, n (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Moderate</td><td align="center" rowspan="1" colspan="1">16 (27.6%)</td><td align="center" rowspan="1" colspan="1">47 (63.5%)</td><td align="center" rowspan="2" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Severe</td><td align="center" rowspan="1" colspan="1">42 (72.4%)</td><td align="center" rowspan="1" colspan="1">27 (36.5%)</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>COPD=chronic obstructive pulmonary disease; NYHA=New York Heart
Association; PAP=pulmonary artery pressure</p></fn><fn id="TFN3"><label>*</label><p>Pearson's chi-square test or Fisher's exact test. </p></fn><fn id="TFN4"><label>**</label><p>Student's-t test.</p></fn><fn id="TFN5"><label>***</label><p>Mann-Whitney U test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Preoperative blood results and haematological parameters of patients.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Preoperative blood results and haematological
parameters</th><th align="center" rowspan="1" colspan="1">CABG + mitral annuloplasty Group 1 (n=58) Median
(min-max)</th><th align="center" rowspan="1" colspan="1">Isolated CABG Group 2 (n=74) Median (min-max)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Haemoglobin (mg/dL)</td><td align="center" rowspan="1" colspan="1">13.6 (10.4-15.5)</td><td align="center" rowspan="1" colspan="1">14.0 (10.4-16.5)</td><td align="center" rowspan="1" colspan="1">0.36<xref ref-type="table-fn" rid="TFN6">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Haematocrit (%)</td><td align="center" rowspan="1" colspan="1">40.7 (30.6-48.1)</td><td align="center" rowspan="1" colspan="1">42.6 (30.5-48.9)</td><td align="center" rowspan="1" colspan="1">0.31<xref ref-type="table-fn" rid="TFN6">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dL)</td><td align="center" rowspan="1" colspan="1">0.90 (0.56-1.83)</td><td align="center" rowspan="1" colspan="1">0.90 (0.50-1.89)</td><td align="center" rowspan="1" colspan="1">0.64<xref ref-type="table-fn" rid="TFN6">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Urea (mg/dL)</td><td align="center" rowspan="1" colspan="1">41 (31-68)</td><td align="center" rowspan="1" colspan="1">43 (31-49)</td><td align="center" rowspan="1" colspan="1">0.82<xref ref-type="table-fn" rid="TFN6">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Leukocyte count (x103/&#x000b5;L)</td><td align="center" rowspan="1" colspan="1">7.75 (5.90-9.70)</td><td align="center" rowspan="1" colspan="1">7.60 (5.10-10.20)</td><td align="center" rowspan="1" colspan="1">0.92<xref ref-type="table-fn" rid="TFN6">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Thrombocyte count (x103/&#x000b5;L)</td><td align="center" rowspan="1" colspan="1">261 (180-401)</td><td align="center" rowspan="1" colspan="1">255 (147-422)</td><td align="center" rowspan="1" colspan="1">0.41<xref ref-type="table-fn" rid="TFN6">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">C-reactive protein (mg/L)</td><td align="center" rowspan="1" colspan="1">0.55 (0.17-1.76)</td><td align="center" rowspan="1" colspan="1">0.54 (0.16-1.87)</td><td align="center" rowspan="1" colspan="1">0.97<xref ref-type="table-fn" rid="TFN6">**</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN6"><label>**</label><p>Mann-Whitney U test. CABG=coronary artery bypass grafting</p></fn></table-wrap-foot></table-wrap><p>The intraoperative and postoperative data of the patients were shown in <xref ref-type="table" rid="t4">Table 4</xref>. Aortic cross-clamp time
(<italic>P</italic>=0.0001), CBP time (<italic>P</italic>=0.0001), intubation
time (<italic>P</italic>=0.0001), use of inotropic support
(<italic>P</italic>=0.004) and length of hospital stay (<italic>P</italic>=0.01)
presence were significantly different between the groups. The average number of
distal anastomoses was 3.53&#x000b1;0.60 in Group 1, and 3.54&#x000b1;0.86 in Group 2,
which was not statistically different between the groups (<italic>P</italic>=0.92).
LIMA was used in 55 (94.8%) patients in Group 1 and 68 (91.9%) patients in Group
2.</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Preoperative blood results and haematological parameters of patients.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">CABG + mitral annuloplasty Group 1 (n=58)
Mean&#x000b1;SD</th><th align="center" rowspan="1" colspan="1">Isolated CABG Group 2 (n=74) Mean&#x000b1;SD</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CCT, minute</td><td align="center" rowspan="1" colspan="1">90.29&#x000b1;6.99</td><td align="center" rowspan="1" colspan="1">59.00&#x000b1;10.62</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN9">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">CPB time, minute</td><td align="center" rowspan="1" colspan="1">132.09&#x000b1;6.64</td><td align="center" rowspan="1" colspan="1">91.19&#x000b1;11.69</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN9">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Intubation time, hours</td><td align="center" rowspan="1" colspan="1">8.00&#x000b1;5.06</td><td align="center" rowspan="1" colspan="1">6.71&#x000b1;6.12</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN9">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Amount of drainage, mL</td><td align="center" rowspan="1" colspan="1">382.7&#x000b1;211.6</td><td align="center" rowspan="1" colspan="1">367.6&#x000b1;192.2</td><td align="center" rowspan="1" colspan="1">0.51<xref ref-type="table-fn" rid="TFN9">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Number of distal anastomoses</td><td align="center" rowspan="1" colspan="1">3.53&#x000b1;0.60</td><td align="center" rowspan="1" colspan="1">3.54&#x000b1;0.86</td><td align="center" rowspan="1" colspan="1">0.92<xref ref-type="table-fn" rid="TFN9">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Length of intensive care unit stay, hours</td><td align="center" rowspan="1" colspan="1">37.74&#x000b1;31.33</td><td align="center" rowspan="1" colspan="1">30.01&#x000b1;28.09</td><td align="center" rowspan="1" colspan="1">0.15<xref ref-type="table-fn" rid="TFN9">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Length of hospital stay, days</td><td align="center" rowspan="1" colspan="1">7.17&#x000b1;3.16</td><td align="center" rowspan="1" colspan="1">5.85&#x000b1;1.37</td><td align="center" rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="TFN9">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Use of inotropic support, n (%)</td><td align="center" rowspan="1" colspan="1">18 (31.0%)</td><td align="center" rowspan="1" colspan="1">8 (10.8%)</td><td align="center" rowspan="1" colspan="1">0.004<xref ref-type="table-fn" rid="TFN9">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Use of blood products, n (%)</td><td align="center" rowspan="1" colspan="1">32 (55.2%)</td><td align="center" rowspan="1" colspan="1">30 (40.5%)</td><td align="center" rowspan="1" colspan="1">0.10<xref ref-type="table-fn" rid="TFN8">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><p>CABG=coronary artery bypass grafting; CCT=cross-clamp time;
CPB=cardiopulmonary bypass</p></fn><fn id="TFN8"><label>*</label><p>Pearson's chi-square test or Fisher's exact test. </p></fn><fn id="TFN9"><label>**</label><p>Mann-Whitney U test.</p></fn></table-wrap-foot></table-wrap><p>Evaluations of the early postoperative complications were summarized in <xref ref-type="table" rid="t5">Table 5</xref>. Postoperative AF was significantly
different between groups (<italic>P</italic>=0.005) and other parameters were not
significantly different between the groups. There were 6 hospitalizations for heart
failure in Group 1 (10.6%) and 19 in Group 2 (27.1%) (<italic>P</italic>=0.02).
Mortality in the hospital and in the 1<sup>st</sup> postoperative month occurred in
2 (3.4%) patients in Group 1 and in 4 (5.4%) patients in Group 2, which was not
statistically different between the groups (<italic>P</italic>=0.69). The causes of
operative mortality were low cardiac output syndrome in 3 patients and multiple
organ failure, mediastinitis and pneumonia in one patient each.</p><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Evaluation of the early postoperative complications.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Complications</th><th align="center" rowspan="1" colspan="1">CABG + mitral annuloplasty Group 1 (n=58)</th><th align="center" rowspan="1" colspan="1">Isolated CABG Group 2 (n=74)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Neurological events, n (%)</td><td align="center" rowspan="1" colspan="1">3 (5.2%)</td><td align="center" rowspan="1" colspan="1">5 (6.8%)</td><td align="center" rowspan="1" colspan="1">1.00<xref ref-type="table-fn" rid="TFN11">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Respiratory event, n (%)</td><td align="center" rowspan="1" colspan="1">10 (17.2%)</td><td align="center" rowspan="1" colspan="1">16 (21.6%)</td><td align="center" rowspan="1" colspan="1">0.53<xref ref-type="table-fn" rid="TFN11">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Renal disorder, n (%)</td><td align="center" rowspan="1" colspan="1">2 (3.4%)</td><td align="center" rowspan="1" colspan="1">4 (%.4%)</td><td align="center" rowspan="1" colspan="1">0.69<xref ref-type="table-fn" rid="TFN11">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">IABP, n (%)</td><td align="center" rowspan="1" colspan="1">6 (10.3%)</td><td align="center" rowspan="1" colspan="1">5 (6.8%)</td><td align="center" rowspan="1" colspan="1">0.53<xref ref-type="table-fn" rid="TFN11">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Bleeding revision, n (%)</td><td align="center" rowspan="1" colspan="1">3 (5.2%)</td><td align="center" rowspan="1" colspan="1">2 (2.7%)</td><td align="center" rowspan="1" colspan="1">0.65<xref ref-type="table-fn" rid="TFN11">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Sternal infection, n (%)</td><td align="center" rowspan="1" colspan="1">5 (8.6%)</td><td align="center" rowspan="1" colspan="1">4 (5.4%)</td><td align="center" rowspan="1" colspan="1">0.51<xref ref-type="table-fn" rid="TFN11">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Sternal revision, n (%)</td><td align="center" rowspan="1" colspan="1">3 (5.2%)</td><td align="center" rowspan="1" colspan="1">2 (2.7%)</td><td align="center" rowspan="1" colspan="1">0.65<xref ref-type="table-fn" rid="TFN11">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative new-onset AF, n (%)</td><td align="center" rowspan="1" colspan="1">22 (37.9%)</td><td align="center" rowspan="1" colspan="1">12 (16.2%)</td><td align="center" rowspan="1" colspan="1">0.005<xref ref-type="table-fn" rid="TFN11">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN10"><p>AF=atrial fibrillation; CABG=coronary artery bypass grafting;
IABP=intra-aortic balloon pump</p></fn><fn id="TFN11"><label>*</label><p>Pearson's chi-square test or Fisher's exact test.</p></fn></table-wrap-foot></table-wrap><p>Clinical follow-up was completed with 117 (88.6%) patients, with a mean follow-up
period of 51.3 &#x000b1; 26.8 months. There were 3 deaths in the CABG plus mitral
ring annuloplasty group over a mean follow-up of 45.9 &#x000b1; 26.0 months, yielding
an estimated actuarial 8-year survival rate of 90.4% &#x000b1; 4.1%. NYHA class in
this group improved from 3.6 &#x000b1; 0.5 to 1.3 &#x000b1; 0.5 during follow-up.
There were 6 deaths in the isolated CABG group over a mean follow-up of 55.6
&#x000b1; 26.8 months, yielding an estimated actuarial 8-year survival rate of
84.1%&#x000b1;4.7%. NYHA class in this group improved from 2.5 &#x000b1; 0.6 to 2.1
&#x000b1; 0.7 during follow-up.</p><p>Long-term survival was not different between groups (<italic>P</italic>=0.56, 95% CI:
91.64 (88.23-95.05) (<xref ref-type="fig" rid="f1">Figure 1</xref>). Preoperative
and postoperative NYHA class were significantly different between the groups
(<italic>P</italic>=0.0001).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Kaplan-Meier survival curves of our patients undergone isolated CABG and
CABG plus MRA.</p></caption><graphic xlink:href="rbccv-32-06-0508-g01"/></fig>
</p><p>Follow-up TTE was performed on all surviving patients 6 months and 1 year after
surgery. IMR was improved in 51 (92.7%) patients in the MRA plus CABG group,
compared with 47 (67.1%) patients in the CABG alone group, which was statistically
different between the groups (<italic>P</italic>=0.001). In the echocardiographic
evaluation of survived patients with severe mitral regurgitation, 39 (95.1%)
patients in Group 1 and 13 (56.5%) patients in Group 2 had reduction in the degree
of mitral regurgitation (<italic>P</italic>=0.0001) in the 1-year follow-up.</p><p>In the echocardiographic evaluation of survived patients with severe moderate
regurgitation, 11 (84.6%) patients in Group 1 and 24 (51.1%) patients in Group 2 had
reduction in the degree of mitral regurgitation (<italic>P</italic>=0.003) in the
1-year follow-up.</p><p>The echocardiographic data of the survived patients (preoperative, 6<sup>th</sup> and
12<sup>th</sup> postoperative months) and comparison of the echocardiographic
data in groups and between the groups were depicted in <xref ref-type="table" rid="t6">Table 6</xref>. Postoperative ejection fraction (EF) was significantly
improved in Group 1 and was not significant in Group 2 (<italic>P</italic>=0.0001
for Group 1, <italic>P</italic>=0.22 for Group 2).</p><table-wrap id="t6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Comparison of intragroup and intergroup for preoperative and 6th and 12th
postoperative months echocardiographic data.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">CABG + mitral annuloplasty Group 1 (n=58) Median
(min-max)</th><th align="center" rowspan="1" colspan="1">Isolated CABG Group 2 (n=74) Median (min-max)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Preoperative EF (%)</td><td align="center" rowspan="1" colspan="1">40 (25-50)</td><td align="center" rowspan="1" colspan="1">40 (20-55)</td><td align="center" rowspan="1" colspan="1">0.19<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative 6 months EF (%)</td><td align="center" rowspan="1" colspan="1">45 (30-55)</td><td align="center" rowspan="1" colspan="1">40 (20-55)</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative 12 months EF (%)</td><td align="center" rowspan="1" colspan="1">45 (35-60)</td><td align="center" rowspan="1" colspan="1">40 (20-55)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN13">*</xref></td><td align="center" rowspan="1" colspan="1">0.22<xref ref-type="table-fn" rid="TFN13">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Preoperative LVESD (mm)</td><td align="center" rowspan="1" colspan="1">49 (45-54)</td><td align="center" rowspan="1" colspan="1">46 (42-51)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative 6 months LVESD (mm)</td><td align="center" rowspan="1" colspan="1">46 (43-51)</td><td align="center" rowspan="1" colspan="1">45 (42-51)</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative 12 months LVESD (mm)</td><td align="center" rowspan="1" colspan="1">43 (40-48)</td><td align="center" rowspan="1" colspan="1">45 (42-50)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN13">*</xref></td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN13">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Preoperative LVEDD (mm)</td><td align="center" rowspan="1" colspan="1">60 (56-65)</td><td align="center" rowspan="1" colspan="1">57 (53-62)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative 6 months LVEDD (mm)</td><td align="center" rowspan="1" colspan="1">57 (54-62)</td><td align="center" rowspan="1" colspan="1">57 (54-61)</td><td align="center" rowspan="1" colspan="1">0.18<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative 12 months LVEDD (mm)</td><td align="center" rowspan="1" colspan="1">54 (50-58)</td><td align="center" rowspan="1" colspan="1">56 (53-61)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN13">*</xref></td><td align="center" rowspan="1" colspan="1">0.11<xref ref-type="table-fn" rid="TFN13">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Preoperative LVESV (mm)</td><td align="center" rowspan="1" colspan="1">91 (83-97)</td><td align="center" rowspan="1" colspan="1">84 (76-92)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative 6 months LVESV (mm)</td><td align="center" rowspan="1" colspan="1">73 (67-84)</td><td align="center" rowspan="1" colspan="1">84.5 (75-91)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative 12 months LVESV (mm)</td><td align="center" rowspan="1" colspan="1">61 (54-75)</td><td align="center" rowspan="1" colspan="1">85 (75-94)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN13">*</xref></td><td align="center" rowspan="1" colspan="1">0.43<xref ref-type="table-fn" rid="TFN13">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Preoperative LVEDV (mL)</td><td align="center" rowspan="1" colspan="1">137 (125-145)</td><td align="center" rowspan="1" colspan="1">128 (117-137)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative 6 months LVEDV (mL)</td><td align="center" rowspan="1" colspan="1">121 (112-125)</td><td align="center" rowspan="1" colspan="1">127 (120-138)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative 12 months LVEDV (mL)</td><td align="center" rowspan="1" colspan="1">109 (102-116)</td><td align="center" rowspan="1" colspan="1">127 (120-140)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN13">*</xref></td><td align="center" rowspan="1" colspan="1">0.16<xref ref-type="table-fn" rid="TFN13">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Preoperative EROA (mm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">42 (32-48)</td><td align="center" rowspan="1" colspan="1">28 (24-42)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative 6 months EROA (mm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">21 (18-23)</td><td align="center" rowspan="1" colspan="1">29 (25-43)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative 12 months EROA (mm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">18 (16-20)</td><td align="center" rowspan="1" colspan="1">30 (25-46)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN13">*</xref></td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN13">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Preoperative RV (mL)</td><td align="center" rowspan="1" colspan="1">63 (45-73)</td><td align="center" rowspan="1" colspan="1">40 (32-62)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative 6 months RV (mL)</td><td align="center" rowspan="1" colspan="1">33 (23-42)</td><td align="center" rowspan="1" colspan="1">40 (28-58)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative 12 months RV (mL)</td><td align="center" rowspan="1" colspan="1">20 (17-29)</td><td align="center" rowspan="1" colspan="1">42 ( 25-63)</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN14">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="TFN13">*</xref></td><td align="center" rowspan="1" colspan="1">0.005<xref ref-type="table-fn" rid="TFN13">*</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN12"><p>CABG=coronary artery bypass grafting; EF=ejection fraction; LVED=left
ventricle end-diastolic diameter; LVEF=left ventricular ejection
fraction; LVESD=left ventricle end-systolic diameter; LVEDV=left
ventricle end-diastolic volume; LVESV=left ventricle endsystolic volume;
RV=regurgitant volume; EROA=effective regurgitant orifice area</p></fn><fn id="TFN13"><label>*</label><p>Friedman test.</p></fn><fn id="TFN14"><label>**</label><p>Mann-Whitney U test.</p></fn></table-wrap-foot></table-wrap><p>Postoperative LVESD, LVEDD, LVESV, LVEDV, RV and EROA were significantly decreased in
Group 1. LVESD was significantly decreased in Group 1 (<italic>P</italic>=0.001),
EROA (<italic>P</italic>=0.0001) and RV dimensions (<italic>P</italic>=0.005) was
significantly decreased in Group 2.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>We evaluated the efficacy of concomitant CABG plus mitral ring annuloplasty (MRA)
compared with CABG alone in patients with moderate and severe IMR. In the present
study, we found that combined CABG and MRA in patients with moderate and severe IMR
resulted in a greater decrease of early postoperative mitral regurgitation than CABG
alone. We have observed that, in addition to the CABG, MRA is associated with
improved functional capacity. Patients in both groups had low early and late
mortality rates, despite the presence of impaired LVEF and moderate and severe MR.
We have observed that early-, mid- and long-term mortality was not significantly
different between the groups.</p><p>Mitral repair in addition to CABG was associated with better NHYA functional class
and improvement in EF and decrease in LVESD, LVEDD, LVESV, LVEDV, EROA and
regurgitation volume.</p><p>Approximately 20% of MR is ischemic and associated with myocardial
infarction<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. IMR is an
important complication of myocardial infarction and observed in 40% of patients with
this condition. Regurgitation is caused by annular dilation and papillary muscle
displacement in an anatomically normal valve<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p><p>IMR associated with coronary artery disease can occur in an acute or chronic
fashion<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Acute
ischemic mitral regurgitation was an exclusion criteria in our study.</p><p>Chronic IMR is still a significant clinical problem. It is present in 10-20% of
patients with coronary artery disease and is associated with a worse prognosis after
myocardial infarction and subsequent revascularization. Currently, CABG combined
with restrictive annuloplasty is the most commonly performed surgical
procedure<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>Chronic mitral regurgitation is commonly accompanied with left ventricular segmentary
wall motion abnormality in one or more LV wall with occlusion or stenosis of the
culprit vessel which occurs 16 days after acute myocardial infarction<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>.</p><p>Mitral regurgitation is graded mild, moderate or severe based on echocardiographic
and ventriculography criteria<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>.
EROA criteria for severe mitral regurgitation was 0.4 cm<sup>2</sup> and RV criteria
was 50 mL in patients without ischemia, EROA criteria for severe mitral
regurgitation was 0.2 cm<sup>2</sup> and RV criteria was 30 mL in patients with
ischemia<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. We have
performed MRA in patients with EROA 0.2 cm<sup>2</sup> and RV 30 mL in our
study.</p><p>The presence of IMR in addition to coronary artery disease requiring surgical
revascularization is an important topic for both cardiologists and cardiovascular
surgeons. The surgical options for moderate to severe IMR are mitral repair or
replacement in addition to CABG or isolated CABG<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>.</p><p>The patient's symptoms, the severity of mitral regurgitation, repairability of the
mitral valve, ischemic burden and surgical risk are considered for surgical
intervention<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>.</p><p>The surgical options for IMR and the results of surgery are controversial in the
literature<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p><p>Wong et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup> has investigated
the role of MRA in addition to CABG in patients with moderate to severe mitral
regurgitation. In the long-term follow-up the mortality rate for MRA was not
different between the groups, but the degree of mitral regurgitation was
significantly decreased in MRA group.</p><p>Three hundred ninety patients with moderate to severe IMR were involved in a study
and the groups were compared for MRA in addition to CABG. MRA group was associated
with lesser degree of mitral regurgitation and less symptomatic in short-term
follow-up, but in the long-term functional class and survival were not different
between groups<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>. In our study
we have observed better NYHA functional status and lesser degree of mitral
regurgitation in the MRA group, but in the long-term follow-up survival was not
different between the groups.</p><p>Surgical timing is another important issue, because early intervention can prevent
the irreversible myopathic changes consequent to remodeling<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. Fattouch et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup> randomized 102 patients with
moderate mitral regurgitation to CABG or CABG plus mitral repair. CABG plus mitral
repair was associated with decreased LVESD, LVEDD, pulmonary arterial pressure (PAP)
and left atrial size. Similar to their findings we have observed decreased LVESD,
LVEDD, LVESV, LVEDV, PAP, EROA, regurgitation volume and MR degree in patients with
CABG plus MRA.</p><p>The presence of MR has been associated with adverse cardiac events and
mortality<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Isolated CABG
is usually performed in moderate and moderate-to-severe mitral regurgitation in
high-risk patients with poor general performance. Percutaneous mitral repair may be
an option for these patients. On the other hand, in patients with an acceptable risk
profile, mitral repair is performed in IMR in the majority of patients<sup>[<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r22" ref-type="bibr">22</xref>]</sup>. We have performed isolated CABG in patients with high
surgical risk and poor perioperative state.</p><p>Mallidi et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup> observed higher
rate of heart failure and shorter cardiac event free survival in CABG-only patients
who had mild-to-moderate mitral regurgitation, in comparison with patients who had
no regurgitation.</p><p>In contrast to this finding Silberman et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup> has observed higher rate of heart failure in patients with
CABG plus mitral repair in 231 patients. Smith et al.<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup> has involved 301 patients with IMR to their study
and observed that hospitalization for heart failure was similar between isolated
CABG and CABG plus mitral repair groups (13.2% and 14.7%, respectively). In our
study we have observed that hospitalization for heart failure was significantly
higher in patients with isolated CABG group.</p><p>The hospital mortality rate of CABG-only patients who have no mitral regurgitation
ranges from 0 to 6.9% and the rate for CABG-only patients with moderate mitral
regurgitation ranges from 1.8% to 12%<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. Harris et al.<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup> has investigated the role of mitral intervention in 176
patients with moderate IMR and the mortality rate was 9% in CABG group and 21% in
mitral intervention group (<italic>P</italic>=0.047). Silberman et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup> has investigated the role of MRA
in addition to CABG in patients with moderate IMR and have observed similar
mortality rates (7%) between the groups. In our study, we have observed similar
mortality rates in patients with CABG alone and CABG plus MRA (3.4% and 5.4%,
respectively).</p><sec><title>Limitations</title><p>A few limitations of our study deserve mention. This is a single centre
retrospective study. Another limitation is the echocardiographic evaluation of
MR grade and the lack of complete follow-up. Small sample size, especially in
the propensity analysis, is another limitation of this study. The issue of
myocardial viability is also important in surgical management of IMR.
Improvement in the grade of mitral regurgitation with CABG is associated with
functional improvement of dysfunctional but viable myocardium. Viability studies
may have a role for prediction of improvement in mitral regurgitation. We did
not routinely perform viability testing. In addition, we did not examine the
relation between viability test results and improvements in IMR.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Patients who have undergone either CABG alone or CABG plus MRA surgery have
experienced very low early and late mortality rates, despite the presence of
multiple comorbidities, impaired LVEF, and moderate and severe MR. Mitral ring
annuloplasty can be performed safely, concomitantly with CABG, in patients who have
moderate and severe IMR. In such patients, the combined procedure resulted in a
greater decrease in early postoperative MR, LVESD, LVEDD, LVESV, LVEDV and EROA than
CABG alone.</p><p>MRA in addition to CABG is associated with improvement in NHYA functional class.
Prospective studies in a randomized fashion are needed to better define the role and
outcome of MRA in this population.</p><table-wrap id="t8" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HS</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">KSO</td><td align="left" rowspan="1" colspan="1">Agreement to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved;
final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">MI</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; final approval of the version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="other"><p>This study was carried out at Derince Training and Research Hospital, Kocaeli,
Turkey.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akar</surname><given-names>AR</given-names></name><name><surname>Durdu</surname><given-names>S</given-names></name><name><surname>Khalil</surname><given-names>A</given-names></name><name><surname>&#x000d6;zyurda</surname><given-names>&#x000dc;</given-names></name></person-group><article-title>Ischemic mitral regurgitation</article-title><source>Turkish Clinics J Cardiovasc Surg-Special Topics</source><year>2008</year><volume>1</volume><issue>2</issue><fpage>37</fpage><lpage>46</lpage></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>PK</given-names></name><name><surname>Puskas</surname><given-names>JD</given-names></name><name><surname>Ascheim</surname><given-names>DD</given-names></name><name><surname>Voisine</surname><given-names>P</given-names></name><name><surname>Gelijns</surname><given-names>AC</given-names></name><name><surname>Moskowitz</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Surgical treatment of moderate ischemic mitral
regurgitation</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>23</issue><fpage>2178</fpage><lpage>2188</lpage><pub-id pub-id-type="pmid">25405390</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castleberry</surname><given-names>AW</given-names></name><name><surname>Williams</surname><given-names>JB</given-names></name><name><surname>Daneshmand</surname><given-names>MA</given-names></name><name><surname>Honeycutt</surname><given-names>E</given-names></name><name><surname>Shaw</surname><given-names>LK</given-names></name><name><surname>Samad</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Surgical revascularization is associated with maximal survival in
patients with ischemic mitral regurgitation: a 20-year
experience</article-title><source>Circulation</source><year>2014</year><volume>129</volume><issue>24</issue><fpage>2547</fpage><lpage>2556</lpage><pub-id pub-id-type="pmid">24744275</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fattouch</surname><given-names>K</given-names></name><name><surname>Sampognaro</surname><given-names>R</given-names></name><name><surname>Speziale</surname><given-names>G</given-names></name><name><surname>Salardino</surname><given-names>M</given-names></name><name><surname>Novo</surname><given-names>G</given-names></name><name><surname>Caruso</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impact of moderate ischemic mitral regurgitation after isolated
coronary artery bypass grafting</article-title><source>Ann Thorac Surg</source><year>2010</year><volume>90</volume><issue>4</issue><fpage>1187</fpage><lpage>1194</lpage><pub-id pub-id-type="pmid">20868812</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deja</surname><given-names>MA</given-names></name><name><surname>Grayburn</surname><given-names>PA</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Rao</surname><given-names>V</given-names></name><name><surname>She</surname><given-names>L</given-names></name><name><surname>Krejca</surname><given-names>M</given-names></name><etal/></person-group><article-title>Influence of mitral regurgitation repair on survival in the
surgical treatment for ischemic heart failure trial</article-title><source>Circulation</source><year>2012</year><volume>125</volume><issue>21</issue><fpage>2639</fpage><lpage>2648</lpage><pub-id pub-id-type="pmid">22553307</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Czer</surname><given-names>LS</given-names></name><name><surname>Soukiasian</surname><given-names>HJ</given-names></name><name><surname>De Robertis</surname><given-names>M</given-names></name><name><surname>Magliato</surname><given-names>KE</given-names></name><name><surname>Blanche</surname><given-names>C</given-names></name><etal/></person-group><article-title>Ischemic mitral regurgitation: revascularization alone versus
revascularization and mitral valve repair</article-title><source>Ann Thorac Surg</source><year>2005</year><volume>79</volume><issue>6</issue><fpage>1895</fpage><lpage>1901</lpage><pub-id pub-id-type="pmid">15919280</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grigioni</surname><given-names>F</given-names></name><name><surname>Enriquez-Sarano</surname><given-names>M</given-names></name><name><surname>Zehr</surname><given-names>KJ</given-names></name><name><surname>Bailey</surname><given-names>KR</given-names></name><name><surname>Tajik</surname><given-names>AJ</given-names></name></person-group><article-title>emic mitral regurgitation: long-term outcome and prognostic
implications with quantitative Doppler assessment</article-title><source>Circulation</source><year>2001</year><volume>103</volume><issue>13</issue><fpage>1759</fpage><lpage>1764</lpage><pub-id pub-id-type="pmid">11282907</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulack</surname><given-names>BC</given-names></name><name><surname>Englum</surname><given-names>BR</given-names></name><name><surname>Castleberry</surname><given-names>AW</given-names></name><name><surname>Daneshmand</surname><given-names>MA</given-names></name><name><surname>Smith</surname><given-names>PK</given-names></name><name><surname>Perrault</surname><given-names>PL</given-names></name></person-group><article-title>Repair or observe moderate ischemic mitral regurgitation during
coronary artery bypass grafting? Prospective randomized multicenter
data</article-title><source>Ann Cardiothorac Surg</source><year>2015</year><volume>4</volume><issue>3</issue><fpage>266</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">26309829</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fattouch</surname><given-names>K</given-names></name><name><surname>Castrovinci</surname><given-names>S</given-names></name><name><surname>Murana</surname><given-names>G</given-names></name><name><surname>Moscarelli</surname><given-names>M</given-names></name><name><surname>Speziale</surname><given-names>G</given-names></name></person-group><article-title>Surgical management of moderate ischemic mitral valve
regurgitation: where do we stand?</article-title><source>World J Cardiol</source><year>2014</year><volume>6</volume><issue>11</issue><fpage>1218</fpage><lpage>1222</lpage><pub-id pub-id-type="pmid">25429333</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Y&#x00131;ld&#x00131;r&#x00131;r</surname><given-names>A</given-names></name></person-group><article-title>Valvular heart disease associated with coronary artery
disease</article-title><source>Anadolu Kardiyol Derg</source><year>2009</year><volume>9</volume><issue>Suppl 1</issue><fpage>10</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">19581151</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyd</surname><given-names>JH</given-names></name></person-group><article-title>Ischemic mitral regurgitation</article-title><source>Circ J</source><year>2013</year><volume>77</volume><issue>8</issue><fpage>1952</fpage><lpage>1956</lpage><pub-id pub-id-type="pmid">23877709</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agricola</surname><given-names>E</given-names></name><name><surname>Oppizzi</surname><given-names>M</given-names></name><name><surname>Pisani</surname><given-names>M</given-names></name><name><surname>Meris</surname><given-names>A</given-names></name><name><surname>Maisano</surname><given-names>F</given-names></name><name><surname>Margonato</surname><given-names>A</given-names></name></person-group><article-title>Ischemic mitral regurgitation: mechanisms and echocardiographic
classification</article-title><source>Eur J Echocardiogr</source><year>2008</year><volume>9</volume><issue>2</issue><fpage>207</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">17600766</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoghbi</surname><given-names>WA</given-names></name><name><surname>Enriquez-Sarano</surname><given-names>M</given-names></name><name><surname>Foster</surname><given-names>E</given-names></name><name><surname>Grayburn</surname><given-names>PA</given-names></name><name><surname>Kraft</surname><given-names>CD</given-names></name><name><surname>Levine</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Recommendations for evaluation of the severity of native valvular
regurgitation with two-dimensional and Doppler
echocardiography</article-title><source>J Am Soc Echocardiogr</source><year>2003</year><volume>16</volume><issue>7</issue><fpage>777</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">12835667</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vahanian</surname><given-names>A</given-names></name><name><surname>Baumgartner</surname><given-names>H</given-names></name><name><surname>Bax</surname><given-names>J</given-names></name><name><surname>Butchart</surname><given-names>E</given-names></name><name><surname>Dion</surname><given-names>R</given-names></name><name><surname>Filippatos</surname><given-names>G</given-names></name><etal/></person-group><article-title>Guidelines on the management of valvular heart disease: the Task
Force on the Management of Valvular Heart Disease of the European Society of
Cardiology</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><issue>2</issue><fpage>230</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">17259184</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aydin</surname><given-names>C</given-names></name><name><surname>Kara</surname><given-names>I</given-names></name><name><surname>Ay</surname><given-names>Y</given-names></name><name><surname>Inan</surname><given-names>B</given-names></name><name><surname>Basel</surname><given-names>H</given-names></name><name><surname>Yanartas</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ischaemic mitral regurgitation: the effects of ring annuloplasty
and suture annuloplasty repair techniques on left ventricular
re-remodeling</article-title><source>Pak J Med Sci</source><year>2013</year><volume>29</volume><issue>1</issue><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">24353503</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sade</surname><given-names>LE</given-names></name></person-group><article-title>Functional mitral regurgitation</article-title><source>Anadolu Kardiyol Derg</source><year>2009</year><volume>9</volume><issue>Suppl 1</issue><fpage>3</fpage><lpage>9</lpage></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>DR</given-names></name><name><surname>Agnihotri</surname><given-names>AK</given-names></name><name><surname>Hung</surname><given-names>JW</given-names></name><name><surname>Vlahakes</surname><given-names>GJ</given-names></name><name><surname>Akins</surname><given-names>CW</given-names></name><name><surname>Hilgenberg</surname><given-names>AD</given-names></name><etal/></person-group><article-title>Long-term survival after surgical revascularization for moderate
ischemic mitral regurgitation</article-title><source>Ann Thorac Surg</source><year>2005</year><volume>80</volume><issue>2</issue><fpage>570</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">16039207</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mihaljevic</surname><given-names>T</given-names></name><name><surname>Lam</surname><given-names>BK</given-names></name><name><surname>Rajeswaran</surname><given-names>J</given-names></name><name><surname>Takagaki</surname><given-names>M</given-names></name><name><surname>Lauer</surname><given-names>MS</given-names></name><name><surname>Gillinov</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Impact of mitral valve annuloplasty combined with
revascularization in patients with functional ischemic mitral
regurgitation</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>49</volume><issue>22</issue><fpage>2191</fpage><lpage>2201</lpage><pub-id pub-id-type="pmid">17543639</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Kang</surname><given-names>SJ</given-names></name><name><surname>Song</surname><given-names>JM</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Mitral valve repair versus revascularization alone in the
treatment of ischemic mitral regurgitation</article-title><source>Circulation</source><year>2006</year><volume>114</volume><issue>1 Suppl</issue><fpage>I499</fpage><lpage>I503</lpage><pub-id pub-id-type="pmid">16820626</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fattouch</surname><given-names>K</given-names></name><name><surname>Guccione</surname><given-names>F</given-names></name><name><surname>Sampognaro</surname><given-names>S</given-names></name><name><surname>Panzarella</surname><given-names>G</given-names></name><name><surname>Corrado</surname><given-names>E</given-names></name><name><surname>Navarra</surname><given-names>E</given-names></name><etal/></person-group><article-title>Efficacy of adding mitral valve restrictive annuloplasty to
coronary artery bypass grafting in patients with moderate ischemic mitral
valve regurgitation: a randomized trial</article-title><source>J Thorac Cardiovasc Surg</source><year>2009</year><volume>138</volume><issue>2</issue><fpage>278</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">19619766</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borger</surname><given-names>MA</given-names></name><name><surname>Alam</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name><name><surname>Doenst</surname><given-names>T</given-names></name><name><surname>David</surname><given-names>TE</given-names></name></person-group><article-title>Chronic ischemic mitral regurgitation: repair, replace or
rethink?</article-title><source>Ann Thorac Surg</source><year>2006</year><volume>81</volume><issue>3</issue><fpage>1153</fpage><lpage>1161</lpage><pub-id pub-id-type="pmid">16488757</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adademir</surname><given-names>T</given-names></name><name><surname>Alp</surname><given-names>M</given-names></name></person-group><article-title>Should a cardiac surgeon blame himself for replacing a mitral
valve?</article-title><source>Braz J Cardiovasc Surg</source><year>2016</year><volume>31</volume><issue>5</issue><fpage>VI</fpage><lpage>VII</lpage><pub-id pub-id-type="pmid">27982341</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallidi</surname><given-names>HR</given-names></name><name><surname>Pelletier</surname><given-names>MP</given-names></name><name><surname>Lamb</surname><given-names>J</given-names></name><name><surname>Desai</surname><given-names>N</given-names></name><name><surname>Sever</surname><given-names>J</given-names></name><name><surname>Christakis</surname><given-names>GT</given-names></name><etal/></person-group><article-title>Late outcomes in patients with uncorrected mild to moderate
mitral regurgitation at the time of isolated coronary artery bypass
grafting</article-title><source>J Thorac Cardiovasc Surg</source><year>2004</year><volume>127</volume><issue>3</issue><fpage>636</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">15001891</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberman</surname><given-names>S</given-names></name><name><surname>Merin</surname><given-names>O</given-names></name><name><surname>Fink</surname><given-names>D</given-names></name><name><surname>Alshousha</surname><given-names>A</given-names></name><name><surname>Shachar</surname><given-names>S</given-names></name><name><surname>Tauber</surname><given-names>R</given-names></name><etal/></person-group><article-title>Does mitral valve annuloplasty improve long-term survival in
patients having moderate ischemic mitral regurgitation undergoing
CABG?</article-title><source>Harefuah</source><year>2014</year><volume>153</volume><issue>12</issue><fpage>705</fpage><lpage>754</lpage><page-range>705-8, 754</page-range><pub-id pub-id-type="pmid">25654909</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tekumit</surname><given-names>H</given-names></name><name><surname>Cenal</surname><given-names>AR</given-names></name><name><surname>Uzun</surname><given-names>K</given-names></name><name><surname>Tataroglu</surname><given-names>C</given-names></name><name><surname>Akinci</surname><given-names>E</given-names></name></person-group><article-title>Ring annuloplasty in chronic ischemic mitral regurgitation
encouraging early and midterm results</article-title><source>Tex Heart Inst J</source><year>2009</year><volume>36</volume><issue>4</issue><fpage>287</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">19693300</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>KM</given-names></name><name><surname>Sundt 3rd</surname><given-names>TM</given-names></name><name><surname>Aeppli</surname><given-names>D</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>Barzilai</surname><given-names>B</given-names></name></person-group><article-title>Can late survival of patients with moderate ischemic mitral
regurgitation be impacted by intervention on the valve?</article-title><source>Ann Thorac Surg</source><year>2002</year><volume>74</volume><issue>5</issue><fpage>1468</fpage><lpage>1475</lpage><pub-id pub-id-type="pmid">12440594</pub-id></element-citation></ref></ref-list></back></article>